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To assess the relation between age at onset and disease severity in facioscapulohumeral mus-
cular dystrophy (FSHD).
Methods
In this prospective cross-sectional study, we matched adult patients with FSHD with an early
disease onset with 2 sex-matched FSHD control groups with a classic onset; the first group was
age matched, and the second group was disease duration matched. Genetic characteristics,
muscle performance, respiratory functioning, hearing loss, vision loss, epilepsy, educational
level, and work status were compared with the 2 control groups.
Results
Twenty-eight patients with early-onset FSHD were age (n = 28) or duration (n = 27) matched
with classic-onset patients. Patients with early-onset FSHD had more severe muscle weakness
(mean FSHD clinical score 11 vs 5 in the age-matched and 9 in the duration-matched group, p <
0.05) and a higher frequency of wheelchair dependency (57%, 0%, and 30%, respectively, p <
0.05). In addition, systemic features were more frequent in early-onset FSHD, most important,
hearing loss, decreased respiratory function and spinal deformities. There was no difference in
work status. Genetically, the shortest D4Z4 repeat arrays (2–3 units) were found exclusively in
the early-onset group, and the largest repeat arrays (8–9 units) were found only in the classic-
onset groups. De novo mutations were more frequent in early-onset patients (46% vs 4%).
Conclusions
Patients with early-onset FSHDmore often have severe muscle weakness and systemic features.
The disease severity is greater than in patients with classic-onset FSHD who are matched for
disease duration, suggesting that the progression is faster in early-onset patients.
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Facioscapulohumeral dystrophy (FSHD; Online Mendelian
Inheritance in Man 158900), one of the most common adult
muscle diseases, is a hereditary, progressive muscular dys-
trophy with a striking disease heterogeneity both between and
within families. Consequently, predicting disease severity and
progression rate is very challenging in FSHD.
FSHD has historically been divided into 2 clinical subgroups:
early-onset FSHD, with facial weakness before the age of 5
years and scapulohumeral weakness before the age of 10 years,1
and classic FSHD, with a typical onset between 15 and 30 years
but often diagnosed throughout the adult lifespan.2,3 An esti-
mated 7% to 15% of patients with FSHD have the early-onset
subtype.1,4,5 Patients with early-onset FSHD have been de-
scribed with amore severe disease1,6,7; however, what is unclear
is whether early-onset FSHD is inherently a more severe,
rapidly progressing disease or if these patients are simply more
severe as a result of longer disease duration. To the best of our
knowledge, no study has systematically attempted to verify this
observation. The finding of early onset as a prognostic factor
and its underlying causes would facilitate patient counseling,
clinical management, and trial readiness.
This study investigates whether patients with an early onset of
symptoms are different from patients with a classic onset re-
garding genotype, hearing loss, vision loss, epilepsy, educational
level, muscle and respiratory functioning, and work status.
Methods
Patient recruitment
This prospective cross-sectional case-control study was per-
formed at the Radboud University Medical Center, Nijmegen,
the Netherlands, between September 2016 and January 2017.
Eligible participants had genetically confirmed FSHD1.1 Early-
onset patients (patients who fulfilled the clinical criteria for early-
onset FSHD1) were recruited via the Dutch national FSHD
registry8 and among the population known at the Neurology
Department of the Radboud University Medical Center, a ter-
tiary referral center for patients with FSHD. Participants with
classic-onset FSHDwere recruited among participants in a large
observational cohort study conducted in 2014 to 2015 (n = 203
participants with FSHD, age 18–84 years).9 Asymptomatic
mutation carriers and patients with FSHD2 were excluded.
Participants werematched by sex and by age or disease duration.
Standard protocol approvals, registrations,
and patient consents
All participants provided written informed consent, and the
Medical Ethics Review Committee region Arnhem-Nijmegen
approved the study.
Clinical assessment
Age at onset was retrieved from the medical file to minimize
the effect of recall bias. If this was not available, a patient-
reported age at onset was used. Information on hearing
difficulties, visual problems, cardiac abnormalities, re-
spiratory abnormalities, CNS complications, educational
level, and work status was obtained from medical files and
patient questionnaires. Clinical assessments were per-
formed at the outpatient clinic of the Radboud University
Medical Center and included manual muscle testing
(shoulder external rotators, elbow flexors, knee extensors,
foot dorsiflexors, and foot plantar flexors), the FSHD
clinical score (range 0–15, 0 = unaffected, 15 = severe in-
volvement of facial, upper limb, leg, scapular and pelvic
girdle, and abdominal muscles10), and visual inspection of
the spine (scoliosis and/or lumbar hyperlordosis classified
as normal/mild/severe). Respiratory function was assessed
with a handheld spirometer with a face mask (MicroLoop,
MicroMedical, Chatham, IL), and the percentage of
expected forced vital capacity (based on sex and height)
was reported.
Genetic analysis
Genetic analysis of peripheral blood mononuclear cells
(PBMCs) was performed at the Department of Human Ge-
netics of the Leiden University Medical Center, the Nether-
lands, and consisted of pulsed field gel electrophoresis for the
sizing of the D4Z4 repeats on chromosomes 4 and 10, hap-
lotype analysis by hybridization of pulsed field gel electro-
phoresis blots with probes A and B in combination with
PCR-based simple sequence length polymorphism
analysis,11,12 and methylation analysis of the D4Z4 repeat at
the FseI restriction site in the proximal unit of the D4Z4
array.13,14 Methylation values are expressed as the Delta1
score, that is, the observed methylation minus the predicted
methylation based on the D4Z4 repeat size.15
Statistics
All eligible participants with early-onset FSHDwere invited for
participation and after inclusion were matched with classic-
onset patients 2 times in a 1:1 way. Descriptive statistics were
applied to describe patient characteristics, with continuous data
reported as mean ± SD. For comparing motor scores between
2 groups, 2-tailed t tests were used for numerical data, and
the Fisher exact test was used for categorical data. The primary
aim was to investigate whether early onset is a risk factor for
more severe disease that is independent of current age or dis-
ease duration. We therefore compared the early-onset group
with both control groups separately (comparing group 1 with
group 2 and group 1 with group 3) and did not adjust for
3 group analyses. The Pearson correlation coefficient was
calculated for correlations between genotype and phenotype.
Glossary
FSHD = facioscapulohumeral dystrophy; PBMC = peripheral blood mononuclear cell.
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After data analysis, a subdivision in the early-onset group
was suspected; therefore, additional subgroup analyses were
performed on patients with an onset before the age of 8 years
and onset between 8 and 10 years. We performed linear re-
gression analyses to compare age at onset with disease se-
verity. Relations with values of p < 0.05 were considered
statistically significant. Statistical analyses were performed
with GraphPad Prism.16
Data availability
The data from this study cannot be made publicly available
because no patient approval has been obtained for sharing
coded data. Output of statistical analyses (GraphPad Prism)
will be made available on reasonable request.
Results
Demographics
A total of 62 patients with early-onset FSHDwere identified;
28 participated. The exclusion reasons for the other 34
patients were as follows: 1 had died, 4 had FSHD type 2, 12
could not be contacted, and 17 were not able to come to the
study location or refused participation. The participants
were matched with 28 age- and sex-matched patients with
classic-onset FSHD and with 27 duration- and sex-matched
patients with classic-onset FSHD (figure 1, demographics
given in table 1). In the early-onset group, age at onset was
stated in the medical file in 12 of 28 patients and was similar
to the patient-reported age at onset in 10 patients. In the
other 2 patients, the age at onset was 2 and 3 years earlier
than reported by the patient.
Muscle weakness
The patients with early-onset FSHD had more severe muscle
weakness defined by the FSHD clinical score, the Medical
Research Council sum score, and the percentage of wheel-
chair dependency (table 1 and figure 2). In the early-onset
group, the frequency of wheelchair dependency was higher; it
occurred at an earlier age and after shorter disease duration.
The early-onset population had a smaller variability in the
severity of muscle weakness. There was a ceiling effect in the
FSHD clinical score, mostly in the early-onset group, for
wheelchair-dependent patients.
Systemic features
CNS complications such as hearing loss, vision loss, and epi-
lepsy are summarized in table 2. Hearing loss was diagnosed
between the ages of 1 and 36 years (mean 9 years) in the 5
patients in the early-onset group and at a mean age of 12 years
for the patients in the duration-matched group. Hearing loss
consisted of bilateral high-frequency loss, and 4 of 5 (80%) of
the patients in the early-onset group required hearing aids.
Vision loss was found in 1 early-onset patient in whom Coats
syndrome was diagnosed. Idiopathic epilepsy without struc-
tural brain abnormalities on imaging was found in 2 patients
with early-onset FSHD. Intellectual disability was not observed
in any of the patients, and there was no difference in mean
educational level, although more patients received specialized
education in the early-onset group (5 vs 2 patients). Compli-
cations of severe axial weakness such as spinal deformities and
respiratory complications were more frequent in the early-
onset group. Five patients needed nocturnal noninvasive ven-
tilation starting at a mean age of 46 years. All 5 were wheelchair
dependent and had severe axial weakness.
Genetic characteristics
The mean number of D4Z4 repeat units of the disease allele
in the early-onset patients was significantly lower than in the
classic-onset patients (3.6 vs 6.2 units, table 1). The meth-
ylation value, as measured by the Delta1 score, did not sig-
nificantly differ between the groups. All patients with very
short repeat array sizes (2–3 units) had an early disease
onset, and all patients with large repeat array sizes (8–9
units) had a classic age at onset (figure 3). Systemic features
were seen mostly in patients with short repeats (2–3 units)
but occurred in patients with 5 to 8 units as well. Somatic
mosaicism for the D4Z4 repeat array contraction was found
in 2 patients: 1 early-onset patient had a repeat array size of 2
units in 40% of PBMCs and a normal repeat array size (14
units) in 60%; the classic-onset patient had 8 units in 90% of
PBMCs and 7 units in 10%.
Correlating age at onset with disease severity
In the early-onset group, the age at onset had a bimodal
distribution, with a peak of onset between 0 and 2 years and
between 8 and 10 years (figure 3). Patients 0 to 7 years of age
at onset were clinically more homogeneous with pronounced
Figure 1 Group characteristics
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muscle weakness (FSHD clinical scores 9–15) and with more
frequent systemic features. Patients with an onset age be-
tween 8 and 10 years were genetically and clinically more
heterogeneous, with 5 having a mild clinical severity (FSHD
clinical scores 2–6, wheelchair at a later age or lasting am-
bulant, rarely systemic features) and more frequently familial
cases (table 3).
We assessed the correlation between age at onset and clinical
severity using the age-corrected clinical severity score. In the
early-onset group, age at onset accounted for 43% (R2 = 0.43,
p < 0.0001) of the variability in the age-adjusted clinical se-
verity score compared to 24% (R2 = 0.24, p < 0.0001, figure 4)
in the total cohort.
Discussion
This study shows that disease severity is related to age at
symptom onset in FSHD. Patients with an early age at onset
have more severe muscle weakness and more frequently
systemic features compared to both age-matched and duration-
matched patients with FSHD with a later disease onset.
Figure 2 FSHD clinical score from early-onset patients
compared with the 2 control groups
Mean facioscapulohumeral dystrophy (FSHD) clinical score is significantly
higher in the early-onset group than in both control groups (***p < 0.0001,
*p = 0.03).








Participants, n 28 28 27
Male, % 46 46 44
Age at examination, mean ± SD, y 43 ± 15 44 ± 15 63 ± 8
Age at disease onset, mean ± SD, y 6 ± 3.7 24 ± 7.7 25 ± 9.6
Age at diagnosis, mean ± SD, y 13 ± 6 32 ± 14 37 ± 13
Disease duration from onset, mean ± SD, y 38 ± 14.4 20 ± 14.5 38 ± 14.8
Clinical history
FSHD clinical score (0–15), mean ± SD 10.8 ± 4.2 4.8 ± 2.8a 8.7 ± 3.4a
Medical Research Council sum score (0–50), mean ± SD 31 ± 10 43 ± 5a 36 ± 7
Wheelchair dependency, % 57 0a 30a
Mean age at wheelchair dependency, mean ± SD, y 31 ± 17 —a 58 ± 6
Disease duration at wheelchair dependency, mean ± SD, y 26 ± 15 —a 39 ± 7
Genetic characteristics
D4Z4 repeats, mean ± SD (range), units 3.6 ± 1.3 (2–7) 6.2 ± 1.4 (4–9)a 6.3 ± 1.3 (3–9)a
De novo mutations, n (%) 13 (46) 3 (11)a 3 (11)a
Mosaic mutations, n (%) 1 (4) 1 (4) 2 (7)
Methylation, Delta1 score, mean ± SD (range) −0.5 ± 14 (−34 to 18) −2.2 ± 10 (−23 to 17) −3.8 ± 7 (−20 to 40)
Abbreviation: FSHD = facioscapulohumeral dystrophy.
Delta1 score is the observed methylation minus the predicted methylation based on the D4Z4 repeat size.
a Significantly different from early-onset FSHD, p < 0.05.
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Therefore, age at onset can potentially serve as a prognostic
marker for disease severity. Recognizing this subgroup of
patients with FSHD could improve counseling, clinical man-
agement, and future therapeutic trials.
Patients with an early disease onset experienced severe muscle
weakness and wheelchair dependency at a younger age com-
pared to patients with FSHD with a classic onset. Therefore,
the more severe disease in early-onset FSHD is not explained
by current age or disease duration only. In addition, a shorter
D4Z4 repeat array size (1–3 units) alone was not associated
with a higher frequency of systemic features, meaning that
disease severity is also not explained by repeat array size only.
One possible explanation for the different phenotype could be
the general underlying genetic profile in which theD4Z4 repeat
array size and other modifying factors interact. Because DNA
methylation captures only 1 aspect of the D4Z4 chromatin
structure, in the future, it will be interesting to test variants in
modifiers of other features of the D4Z4 chromatin structure
such as the recently described NuRD and CAF-1 complexes.17
Another explanation could be the particular vulnerability to
DUX4 of the developing muscles and nervous system during
childhood and puberty. An argument for the developmental
instead of degenerative pathophysiology of FSHD could be the
finding that within the early-onset group, but not in the classic-
onset groups, an earlier onset was associatedwith amore severe
phenotype.
This study showed a higher frequency of systemic features
in patients with early-onset FSHD, thereby confirming
Table 2 Systemic features in patients with early-onset and classic-onset FSHD
Systemic features Early-onset FSHD (n = 28)
Age-matched
classic-onset
FSHD (n = 28)
Duration-matched
classic-onset
FSHD (n = 27)
FSHD-related hearing loss, na 5 0 1
Hearing aids, n 4 0 0
FSHD-related vision loss (Coats syndrome), n 1 0 0
Epilepsy without other known cause, n 2 0 0
Severe spinal deformities, n 14 0 5
Noninvasive ventilation, n 6 0 2
Forced vital capacity, mean ± SD, % of expected 56 ± 22 79 ± 14 75 ± 17
Educational level, ISCED 2011 4.7 ± 1.8 4.5 ± 1.6 4.2 ± 1.9
Work status, % patients with paid job or retired after paid job 64 73 58
Abbreviations: FSHD = facioscapulohumeral dystrophy; ISCED = International Standard Classification of Education.
a Defined as high-frequency hearing loss before the age of 65 years without other known cause for hearing loss.
Figure 3 Correlation between the (A) D4Z4 repeat array size and (B) FSHD clinical score and distribution of age at onset in
the early-onset FSHD group
Correlation with a Pearson r of −0.34 (p = 0.003). FSHD = facioscapulohumeral dystrophy.
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results of earlier studies.1,18,19 These findings emphasize
the need for regular screening of hearing loss, retinal ab-
normalities, and pulmonary complications in early-onset
patients.20 We did not find patients with intellectual dis-
ability in our group and therefore cannot confirm the in-
tellectual disability as part of FSHD observed in other
studies. Patients with intellectual disability reported in
several case reports frequently showed other features such
as dysmorphic features21 and epilepsy,7,21 which could sug-
gest other comorbidity. In 20% of the early-onset patients,
asymptomatic cardiac arrhythmias were found without clini-
cally relevant symptoms, which is in concordance with the
available literature.22–24
Two additional factors that could facilitate prognostication in
FSHD were identified in this study. First, the age at onset was
directly correlated with the FSHD evaluation score in our
early-onset subgroup, while this was not the case for the
classic-onset groups. It is possible, therefore, to hypothesize
that in childhood every disease-free year is important, while in
classic onset, the exact age at onset is contributing far less to
disease severity. Second, our results suggest a faster disease
progression and possibly a developmental pathophysiology in
patients with early-onset FSHD, although this needs confir-
mation in longitudinal studies.
The strengths of this study are the extensive clinical and
genetic assessments and the 2 control groups. One limitation
is the patient-reported age at disease onset with the risk of
recall bias. One could suspect an increased number of fa-
milial cases in the early-onset group because symptoms are
recognized earlier than in sporadic or index cases. However,
the frequency of sporadic cases was much higher in the early-
onset group (46% vs 11%), suggesting that familial cases
were not overrepresented. Second, the absence of patients
with intellectual disability and mildly affected sporadic
patients may represent inclusion bias. Lastly, the current
study is hypothesis generating, and implementation as
a prognostic marker would require a prospective longitudi-
nal follow-up for confirmation.
This study suggests that early onset is a marker for a more
severe disease in FSHD, which facilitates counseling and fu-
ture trial tailoring.








Male participants, n (%) 17 (53) 11 (36)
Age at examination, mean ± SD, y 40 ± 11 48 ± 19
Clinical history
Clinical severity score mean
(range 0-10)
9.06 (6–10) 5.73 (1–10)
FSHD clinical score mean
(range 0–15)
12.9 (9–15) 7.9 (2–14)
Wheelchair dependency, n% 11 (65) 4 (36)
Age at wheelchair dependency,
mean (range), y
23 (7–43) 54 (43–60)
Genetic characteristics
D4Z4 repeats, mean ± SD (range), n 3.33 (2–6) 3.99 (3–7)
De novo mutations, n (%) 11 (65) 2 (18)
Systemic features, n (%)
FSHD-related hearing lossa 5 (29) 1 (9)
Noninvasive ventilation 4 (24) 2 (18)
Abbreviation: FSHD = facioscapulohumeral dystrophy.
a High-frequency hearing loss before the age of 65 years without other
known cause for hearing loss.
Figure 4 Correlation between the age at onset and the FSHD clinical score for (A) all patients (B) early-onset group
CSS = clinical severity score; FSHD = facioscapu-
lohumeral dystrophy.
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